… resistance to EGFR TKIs in a well-defined cohort of NSCLC patients harboring EGFR-activating …
Secondly, we examined the predictive role of BIM deletion in EGFR TKI outcome. …

… tumor changes. This comprehensive review describes the identified mechanisms connected
with intrinsic EGFR-TKI-… among clinically implemented EGFR-TKIs of different generations. …

… , structure-function relationships and ultimately the incorporation of molecular diagnostics
and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms. …

… We continued EGFR TKI therapy following disease progression in addition to subsequent
therapies in 87% of patients (9). The T790M mutation was found at similar frequencies across …

We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR
tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a …

… EGFR could induce PD-L1 expression in vitro and vivo, and EGFR tyrosine kinase inhibitors
(EGFR-TKIs) … It is therefore of significance to study the association between EGFR driver …

… Activating epidermal growth factor receptor (EGFR) gene mutations are a positive
predictive factor for EGFR tyrosine kinase inhibitors (TKIs). For common EGFR mutations (Del19, …

… of EGFR TKI can prolong the median PFS in EGFR TKI-resistant NSCLC patients [33, 34]. …
And the combination of EGFR TKI and chemotherapy targeted EGFR TKI-sensitive and -…

… lesion previously and concurrently with EGFR TKI. Nine of 11 … In conclusion, EGFR TKIs are
effective in the treatment of LM … in NSCLC patients with EGFR TKIs to determine the efficacy …

… growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are just two
different entities in terms of prognosis and treatment response to tyrosine kinase inhibitors (TKIs). …